The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-transplant lymphoproliferative disorders (PTLD).
The purpose of phase II of this clinical trial is to learn if the drugs loncastuximab tesirine and rituximab are effective in participants with post-transplant lymphoproliferative disorders (PTLD).
Subject aged ≥ 18 years.
Histologically confirmed B-cell PTLD (monomorphic and polymorphic) following solid organ transplantation; with or without EBV association.
Measurable disease as defined by the 2014 Lugano Classification as assessed by positron-emission tomography (PET)- computed tomography (CT) or by CT or magnetic resonance imaging (MRI) if the tumor is not fluorodeoxyglucose (FDG)-avid on screening
ECOG Performance Status ≤ 2.
PTLD following liquid transplantation
CNS involvement
Prior treatment for PTLD with the exception of radiation, antivirals, steroids and reduced immunosuppression
Human immunodeficiency virus (HIV) infection
6
Treatment groupsSee each treatment group below.
University of Utah
Lead sponsor
ADC Therapeutics S.A.
Collaborator